Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
N Engl J Med
.
1991 May 9;324(19):1362-5.
doi: 10.1056/NEJM199105093241911.
Authors
A L Hillman
,
J M Eisenberg
,
M V Pauly
,
B S Bloom
,
H Glick
,
B Kinosian
,
J S Schwartz
PMID:
1901959
DOI:
10.1056/NEJM199105093241911
No abstract available
MeSH terms
Cost-Benefit Analysis*
Drug Industry*
Ethics, Professional
Prejudice*
Research Design
United States